Patents by Inventor Hans Jochen Lang

Hans Jochen Lang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20090143473
    Abstract: Use of inhibitors of the cellular Na+/H+ exchanger (NHE) for the production of a medicament for the normalization of serum lipids. The active compounds identified as inhibitors of the cellular Na+/H+ exchanger (NHE) are used for the production of a medicament for the normalization of serum lipids. They are used for the production of a medicament for lowering the blood lipid level and illnesses caused thereby, as well as the endothelial dysfunction syndrome and illness caused thereby.
    Type: Application
    Filed: February 3, 2009
    Publication date: June 4, 2009
    Applicant: SANOFI-AVENTIS DEUTSCHLAND GMBH
    Inventors: Hans Jochen LANG, Hans-Willi JANSEN, Jan-Robert SCHWARK, Heinz-Werner KLEEMANN, Oliver JUNG, Hans-Ludwig SCHAFER, Wolfgang LINZ, Werner KRAMER, Bernward SCHOLKENS, Eugen FALK
  • Patent number: 6908947
    Abstract: The present invention relates to compounds of formula I, in which X1, X2, X3, X4, Y1, Y2, Y3, Y4, R(3), R(4) and R(5) have the meanings mentioned in the specification, their preparation and their use, in particular in pharmaceuticals. The compounds effect the potassium channel or the IKs channel opened by cyclic adenosine monophosphate (cAMP) and are outstandingly suitable as pharmaceutical active compounds, for example for the prophylaxis and therapy of cardiovascular disorders, in particular arrhythmias, for the treatment of ulcers of the gastrointestinal region or for the treatment of diarrheal disorders.
    Type: Grant
    Filed: October 25, 2001
    Date of Patent: June 21, 2005
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Joachim Brendel, Hans Jochen Lang, Uwe Gerlach
  • Publication number: 20040122096
    Abstract: Use of inhibitors of cellular Na+/H+ exchanger (NHE) for the production of a medicament for the normalization of serum lipids
    Type: Application
    Filed: October 8, 2003
    Publication date: June 24, 2004
    Applicant: Hoechst Aktiengesellschaft
    Inventors: Hans Jochen Lang, Hans-Willi Jansen, Jan-Robert Schwark, Heinz-Werner Kleemann, Oliver Jung, Hans-Ludwig Schafer, Wolfgang Linz, Werner Kramer, Bernward Scholkens, Eugen Falk
  • Publication number: 20040097544
    Abstract: The use of an inhibitor of the Na+/H+ exchanger for the production of a medicament for the treatment or prophylaxis of disorders of the central nervous system. Inhibitors of the Na+/H+ exchanger are outstandingly suitable for the production of a medicament for the treatment or prophylaxis of disorders of the central nervous system; derivatives of guanidine are particularly highly suitable; cariporide (HOE 642) is especially suitable.
    Type: Application
    Filed: April 28, 2003
    Publication date: May 20, 2004
    Applicant: Hoechst Marion Roussel Deutschland GMBH
    Inventors: Hans Jochen Lang, Klaus Wirth, Dieter Bingmann, Udo Bonnet, Martin Wiemann
  • Patent number: 6703411
    Abstract: Benzoylguanidines of the formula (I) in which R1 to R4 have the meanings given in the specification and claims are suitable as antiarrhythmic medicaments having a cardioprotective component for infarct prophylaxis and infarct treatment and for the treatment of angina pectoris. The compounds of the invention also preventively inhibit the pathophysiological processes in the formation of ischemically induced damage, in particular in the triggering of ischemically induced cardiac arrhythmias.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: March 9, 2004
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Andreas Weichert, Udo Albus, Hans-Willi Jansen, Heinz-Werner Kleemann, Hans Jochen Lang
  • Patent number: 6600072
    Abstract: Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them. Substituted 1-naphthoylguanidines of the formula I in which R2 to R8 have the meanings indicated in the claims, are suitable as antiarrhythmic pharmaceuticals having a cardioprotective component for infarct prophylaxis and infarct treatment and for the treatment of angina pectoris. They also preventively inhibit the pathophysiological processes in the formation of ischemically induced damage, in particular in the production of ischemically induced cardiac arrhythmias.
    Type: Grant
    Filed: August 14, 2002
    Date of Patent: July 29, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Joachim Brendel, Heinz-Werner Kleeman, Heinrich Christian Englert, Hans Jochen Lang, Udo Albus, Bansi Lal, Anil Vasantrao Ghate
  • Patent number: 6573288
    Abstract: The invention relates to compounds of formula (I) in which the symbols have the meanings given in the claims. Said compounds are inhibitors of the sodium-dependent bicarbonate/chloride ion exchanger which can be used as medicines for the prophylaxis or treatment of a wide range of diseases, for example the treatment and/or prophylaxis of myocardial infarction, angina pectoris, diseases caused by ischaemia, impaired respiration, cardiac ischaemia, ischaemia of the peripheral and central nervous system and stroke, ischaemia of the peripheral organs and limbs and diseases in which cell proliferation is a primary or secondary cause, in the treatment of shock, during surgical interventions and organ transplants or for preserving and storing transplants to be used in surgical interventions.
    Type: Grant
    Filed: November 3, 2000
    Date of Patent: June 3, 2003
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Andreas Weichert, Hans Jochen Lang, Stefan Petry, Jan-Robert Schwark, Heinz-Werner Kleemann, Sabine Faber, Hans-Willi Jansen
  • Publication number: 20030013760
    Abstract: Substituted 1-naphthoylguanidines, process for their preparation, their use as a medicament or diagnostic, and medicament containing them.
    Type: Application
    Filed: August 14, 2002
    Publication date: January 16, 2003
    Inventors: Joachim Brendel, Heinz-Werner Kleemann, Heinrich Christian Englert, Hans Jochen Lang, Udo Albus, Bansi Lal, Anil Vasantrao Ghate
  • Patent number: 6486189
    Abstract: Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them. Compounds of the formula I in which the symbols have the meanings indicated in the claims, have outstanding antiarrhythmic properties and exhibit a cardioprotective component. They can preventively inhibit or greatly decrease the pathophysiological processes in the formation of ischemically induced damage, in particular in the elicitation of ischemically induced cardiac arrhythmias. Moreover, they have a potent inhibitory action on the proliferation of cells.
    Type: Grant
    Filed: October 30, 2001
    Date of Patent: November 26, 2002
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Heinz-Werner Kleemann, Hans Jochen Lang, Jan-Robert Schwark, Andreas Weichert, Sabine Faber, Hans-Willi Jansen
  • Patent number: 6462024
    Abstract: Inhibitors of the sodium-hydrogen exchanger are used for the production of a medicament for decreasing the undesired effects in human and in veterinary medicine which originate from substances which cause damage to the heart when administered acutely or chronically.
    Type: Grant
    Filed: July 11, 2000
    Date of Patent: October 8, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Hans Jochen Lang, Hartmut Rütten, Holger Heitsch, Wolfgang Linz, Bernward Schölkens
  • Patent number: 6444669
    Abstract: 8,8a-Dihydroindeno[1,2-d]thiazole derivatives which carry in the 2-position a substituent having a sulfonamide structure or sulfone structure; processes for their preparation and their use as medicaments The invention relates to polycyclic dihydrothiazoles and to their physiologically acceptable salts and physiologically functional derivatives. Compounds of formula I, in which the radicals are as defined above, and their physiologically acceptable salts and processes for their preparation are described. The compounds are suitable, for example, as anorectics.
    Type: Grant
    Filed: January 17, 2002
    Date of Patent: September 3, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Hans Jochen Lang, Matthias Gossel, Martin Bickel
  • Publication number: 20020103231
    Abstract: 8,8a-Dihydroindeno[1,2-d]thiazole derivatives which carry in the 2-position a substituent having a sulfonamide structure or sulfone structure; processes for their preparation and their use as medicaments
    Type: Application
    Filed: January 17, 2002
    Publication date: August 1, 2002
    Inventors: Gerhard Jaehne, Hans Jochen Lang, Matthias Gossel, Martin Bickel
  • Publication number: 20020072514
    Abstract: The present invention relates to compounds of formula I, 1
    Type: Application
    Filed: October 25, 2001
    Publication date: June 13, 2002
    Applicant: Hoechst Aktiengesellschaft
    Inventors: Joachim Brendel, Hans Jochen Lang, Uwe Gerlach
  • Publication number: 20020055537
    Abstract: Use of inhibitors of the KQT1 channel for preparing a medicament for treating diseases caused by helminths and ectoparasites
    Type: Application
    Filed: November 16, 2001
    Publication date: May 9, 2002
    Applicant: Aventis Pharma Deutschland GMBH
    Inventors: Uwe Gerlach, Joachim Hofmann, Hans Jochen Lang, Aguan Wei
  • Publication number: 20020045761
    Abstract: Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them.
    Type: Application
    Filed: October 30, 2001
    Publication date: April 18, 2002
    Inventors: Heinz-Werner Kleemann, Hans Jochen Lang, Jan-Robert Schwark, Andreas Weichert, Sabine Faber, Hans-Willi Jansen
  • Patent number: 6372917
    Abstract: The invention relates to compounds of formula (I), wherein the symbols have the meanings indicated in the specification. The inventive compounds exhibit dramatic antiarrhythmic proprieties and contain a cardioprotective compound. They can preventively inhibit or strongly reduce pathophysiologic processes upon occurrence of ischemic injuries, especially ischemic cardiac arrhythmia. Said compounds also exhibit a strong inhibiting effect on cellular proliferation.
    Type: Grant
    Filed: January 17, 2001
    Date of Patent: April 16, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Heinz-Werner Kleemann, Hans Jochen Lang, Jan-Robert Schwark, Andreas Weichert, Stefan Petry
  • Patent number: 6369236
    Abstract: The invention relates to compounds of formula (I), wherein the symbols have the meanings indicated in the specification. The inventive compounds exhibit dramatic antiarrhythmic proprieties and contain a cardioprotective compound. They can preventively inhibit or strongly reduce pathophysiologic processes upon occurrence of ischemic injuries, especially ischemic cardiac arrhythmia. Said compounds also exhibit a strong inhibiting effect on cellular proliferation.
    Type: Grant
    Filed: January 18, 2001
    Date of Patent: April 9, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Heinz-Werner Kleemann, Hans Jochen Lang, Jan-Robert Schwark, Stefan Petry, Andreas Weichert
  • Patent number: 6352987
    Abstract: 8,8a-Dihydroindeno[1,2-d]thiazole derivatives which carry in the 2-position a substituent having a sulfonamide structure or sulfone structure; processes for their preparation and their use as medicaments The invention relates to polycyclic dihydrothiazoles and to their physiologically acceptable salts and physiologically functional derivatives. Compounds of formula I, in which the radicals are as defined above, and their physiologically acceptable salts and processes for their preparation are described. The compounds are suitable, for example, as anorectics.
    Type: Grant
    Filed: February 26, 2001
    Date of Patent: March 5, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Gerhard Jaehne, Hans Jochen Lang, Matthias Gossel, Martin Bickel
  • Patent number: 6335451
    Abstract: Five-membered heterocycles having biphenylsulfonyl substitution, process for their preparation, their use as a medicament or diagnostic, and medicament comprising them. Compounds of the formula I in which the symbols have the meanings indicated in the claims, have outstanding antiarrhythmic properties and exhibit a cardioprotective component. They can preventively inhibit or greatly decrease the pathophysiological processes in the formation of ischemically induced damage, in particular in the elicitation of ischemically induced cardiac arrhythmias. Moreover, they have a potent inhibitory action on the proliferation of cells.
    Type: Grant
    Filed: January 21, 1998
    Date of Patent: January 1, 2002
    Assignee: Hoechst Aktiengesellschaft
    Inventors: Heinz-Werner Kleemann, Hans Jochen Lang, Jan-Robert Schwark, Andreas Weichert, Sabine Faber, Hans-Willi Jansen
  • Patent number: 6335363
    Abstract: Use of inhibitors of the KQT1 channel for preparing a medicament for treating diseases caused by helminths and ectoparasites Inhibitors of the KQT1 channel are a novel way of destroying helminths and ectoparasites. For this reason, blockers of the cellular KQT1 channel, which is present in helminths and ectoparasites, are used for preparing a medicament for the treatment of vertebrates and humans infested by helminths or ectoparasites. These KQT1 blockers are used as medicaments on their own or in combination with other medicaments and therapeutic measures. Inhibitors of the KQT1 channel are likewise a novel mechanism of action for phytoparasites such as insects, arachnids, molluscs and nematodes, and consequently, they are used for preparing a crop protection composition.
    Type: Grant
    Filed: December 16, 1999
    Date of Patent: January 1, 2002
    Assignee: Aventis Pharma Deutschland GmbH
    Inventors: Uwe Gerlach, Joachim Hofmann, Hans Jochen Lang, Aguan Wei